Investing.com -- 专注于肥胖和代谢疾病的临床阶段生物制药公司Metsera, Inc. (NASDAQ:MTSR)周一报告的第二季度亏损超出预期,导致其股价下跌8.7%,投资者对这一业绩不佳反应消极。 该公司公布第二季度每股亏损-$0.66,未能达到分析师预估的-$0.63。这一令人失望的财务业绩掩盖了公司在肥胖治疗注射剂和口服激素类似物产品组合方面取得的进展。 Metsera首席...
Source LinkInvesting.com -- 专注于肥胖和代谢疾病的临床阶段生物制药公司Metsera, Inc. (NASDAQ:MTSR)周一报告的第二季度亏损超出预期,导致其股价下跌8.7%,投资者对这一业绩不佳反应消极。 该公司公布第二季度每股亏损-$0.66,未能达到分析师预估的-$0.63。这一令人失望的财务业绩掩盖了公司在肥胖治疗注射剂和口服激素类似物产品组合方面取得的进展。 Metsera首席...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.